Creating new opportunities for single-dose inhalable medicines with our pop-up cardboard dry powder inhaler
So much more than respiratory
We rely on inhalable medicines to treat conditions like asthma, epilepsy, allergies and Parkinson’s. But delivery devices remain clunky, costly, tough on the environment and can be difficult to use.
Rescue medications, anti-infectives and vaccines would all benefit from easy, painless, self-administered delivery too. Meanwhile, bulky plastic capsule inhalers are the only option available for clinical trials.
What these all need is a new single-dose inhaler. An inhaler that is low cost, portable, easy to use and has a low carbon impact. The 1nhaler.®
“It is my belief the 1nhaler will appeal most to patients and prescribers where acute and relatively rare use is expected - for instance, asthma symptoms in stable asthmatics, anaphylaxis and migraine.”
Lars Larsson, MD, PhD, Assoc Professor and CMO, 1nhaler
Portable
Easy to use
Low cost
Low carbon impact
As the world turns away from single-use plastics, we have designed our inhaler to consume as few precious resources as possible, keeping our carbon footprint to a minimum.
~90% cardboard, using FSC-certified card
weighs in at just 1.8g per unit
propellant-free, leveraging advancements in dry powder formulations
electronics-free
minimal API wastage
minimal plastic in landfill
It’s all about performance
“Our current performance data is showing comparability with the market-leading product.”
Helen Muirhead, CSO, 1nhaler
There is no better drug to demonstrate the potential of the patented 1nhaler technology than salbutamol, the most established respiratory drug in the world.
That's why salbutamol for asthma relief is our lead project for technical proof of concept.
Our current performance data is showing comparability with the market-leading salbutamol product for drug deposition to the lungs.
1nhaler development team
-
Helen Muirhead
Chief Scientific Officer
Formerly Head of GSK’s Respiratory Centre of Excellence, responsible for blockbuster Diskus and Ellipta portfolio
-
Frank Chambers
Director, Inhalytic
Formerly AZ and Mylan, specialising in analytical techniques for orally inhaled and nasal NCEs & generic drug products
-
Indre Statkeviciene
MPD Lead
Formerly Technical Project Manager for GSK and Mundipharma
-
Paul Trusty
Materials Scientist
Formerly Senior Technical Director and Global Product Head, GSK and Haleon
-
Andrew Walker
Device Development
Formerly VP Device Development, Vectura and Head of Device Technology, GSK
-
Lars Larsson
Chief Medical Officer
Formerly Medical Director, Licensing, AZ and Head, Clinical Research, Novartis
